Trial Profile

A Phase 1, Open-Label, Dose-escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Patients With Injectable Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 08 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Igrelimogene litadenorepvec (Primary)
Indications Gastrointestinal cancer; Liposarcoma; Pancreatic cancer; Rectal cancer; Solid tumours
Focus Adverse reactions
Acronyms TUNIMO
Sponsors TILT Biotherapeutics

Most Recent Events

09 Sep 2024 According to TILT Biotherapeutics media release, company will present data from this study at the European Society of Medical Oncology (ESMO) Congress 2024.
08 Mar 2024 Planned primary completion date changed from 31 Dec 2023 to 1 Sep 2024.
11 Apr 2023 Planned primary completion date changed from 31 Mar 2023 to 31 Dec 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com